The standard of care and the facts are simple. Men who have aggressive prostate cancer and elect to have radiation therapy will benefit from six months of concurrent hormone therapy (ADT). However, based on recent findings by D’Amico etal, there seems to be a segment of men who will not benefit, but will have inferior [...]
The Prostate Cancer Patient Action Leadership Council will meet in late October to plan advocacy events and activities for 2016. You are invited to join. Please sign up at: http://malecare.org/about/survivor-family-friends-advisory-board/
Xgeva, also known as denosumab, is an injectable medication (injected once a month subcutaneously under the skin in the doctor’s office) that is used to prevent bone fractures and spinal cord compression caused by bone metastases in breast and prostate cancer survivors. Solid tumors in the bone, which is a common site for individuals with [...]
FROM this blog on September 9, 2015 ) According to Michael Jan, MD, and his collaborators at the Karolinska Institute in Stockholm, Sweden those of us who are experiencing high levels of stress need to be cautious. Their findings boil down to the fact that our stress could allow our prostate cancer to kill us. [...]
In an analysis of outcomes reported in the Journal of Clinical Oncology, men who were diagnosed with lymph node-positive prostate cancer (no bone involvement) who went on to receive targeted radiation (adjuvant radiotherapy) enjoyed a survival benefit over those individuals who did not have this therapy. This finding was specifically for men with both low-volume [...]
Are you stressed? If you are and you have been treated for clinically localized prostate cancer you are at a 66% increased risk of dying from your prostate cancer! Research has shown that high stress levels are associated with an increased rate of prostate cancer (PCa) specific mortality among men treated for clinically localized prostate [...]
Many of the posts that I have written discussed the need for evaluating our current advanced prostate cancer drugs in both combinations and their sequencing. We have a number of new drugs, but we don’t understand how best to sequence them, or whether or not some drugs would do better and extend life by taking [...]
Having been diagnosed with prostate cancer does not make you immune to developing another cancer. Look specifically at me; I have now been diagnosed with five different, primary cancers. Not only do we remain susceptible to developing another, unrelated primary cancer, we also are at an increased risk of developing a secondary cancer that is [...]
Men with metastatic castrate resistant prostate cancer (mCRPC) have become fortunate over the last few years as there we now have a number of new drugs available which can extend our life and can also have some palliative effects. However, as we have more treatments being approved, we find that we are faced with a [...]
Intermittent hormone therapy (IHT) as opposed to continuous hormone therapy (CHT) provides a better quality of life (QoL) for men with locally advanced prostate cancer. However, there is a debate created by a few major research protocols that have been inconclusive as to the difference in achieving the ultimate goal, survival despite prostate cancer. Researchers [...]
